Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 46 for:    thalidomide myeloma | Recruiting, Not yet recruiting, Available Studies

The Effects of Huang-Lian-Jie-Du-Tang(HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy (HLJDT-2016)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02467647
Recruitment Status : Recruiting
First Posted : June 10, 2015
Last Update Posted : June 10, 2015
Sponsor:
Collaborator:
Tongji Hospital
Information provided by (Responsible Party):
Shangqin Liu, Wuhan University

Brief Summary:
To investigate the efficacy of the combination of Thalidomide and Huang-Lian-Jie-Du-Tang on the patients with multiple myeloma in maintain therapy.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Thalidomide Drug: HLJDT Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Phase 1 Study of the Effects of Huang-Lian-Jie-Du-Tang(HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy
Study Start Date : January 2015
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma
Drug Information available for: Thalidomide

Arm Intervention/treatment
Experimental: A
Arm A: HLJDT 150ml three times per day for 6 months and Thalidomide 100mg once per day for 6 months
Drug: Thalidomide
Drug: HLJDT
Active Comparator: B
Arm B: Thalidomide 100mg oral once per day for 6 months
Drug: Thalidomide



Primary Outcome Measures :
  1. Overall survival of patients with multiple myeloma treated with Huang-Lian-Jie-Du-Tang(HLJDT) in maintain therapy [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients can take HLJDT

Exclusion Criteria:

  • patients can not take HLJDT

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02467647


Locations
Layout table for location information
China, Hubei
Wuhan University Recruiting
Wuhan, Hubei, China, 430071
Contact: Shangqin Liu, Ph.D    86-27-67812781    ubeliu@aliyun.com   
Sponsors and Collaborators
Wuhan University
Tongji Hospital
Investigators
Layout table for investigator information
Study Chair: Shangqin Liu, PhD Wuhan University

Additional Information:
Publications:
Layout table for additonal information
Responsible Party: Shangqin Liu, Professor, Wuhan University
ClinicalTrials.gov Identifier: NCT02467647     History of Changes
Other Study ID Numbers: HLJDT-2016
First Posted: June 10, 2015    Key Record Dates
Last Update Posted: June 10, 2015
Last Verified: June 2015

Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Thalidomide
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Oren gedoku to
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Leprostatic Agents
Anti-Bacterial Agents
Anti-Infective Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics